Literature DB >> 12211045

Varicella-zoster virus latency in human ganglia.

Peter G E Kennedy1.   

Abstract

Varicella-zoster virus (VZV) is a human herpesvirus which causes varicella (chickenpox) as a primary infection, and, following a variable period during which it remains in latent form in trigeminal and dorsal root ganglia, reactivates in later life to cause herpes zoster (shingles). VZV is a significant cause of neurological disease including post-herpetic neuralgia which may be persistent and highly resistant to treatment, and small and large vessel encephalitis. VZV infections are more frequent with advancing age and in immunocompromised individuals. An understanding of the mechanisms of latency is crucial in developing effective therapies for VZV infections of the nervous system. Such studies have been hampered by the difficulties in working with the virus and also the lack of a good animal model of VZV latency. It is known that the ganglionic VZV burden during latency is low. Two of the key questions that have been addressed are the cellular site of latent VZV and the identity of the viral genes which are transcribed during latency. There is now a consensus that latent VZV resides predominantly in ganglionic neurons with less frequent infection of non-neuronal satellite cells. There is considerable evidence to show that at least five viral genes are transcribed during latency. Unlike herpes simplex virus-1 latency, viral protein expression has been demonstrated during VZV latency. A precise knowledge of which viral genes are expressed is crucial in devising novel antiviral therapy using expressed genes as therapeutic targets. Whether gene expression at both the transcriptional and translational levels is more extensive than currently reported will require much more work and probably new molecular technology. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12211045     DOI: 10.1002/rmv.362

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  27 in total

Review 1.  Neurovirological methods and their applications.

Authors:  P G E Kennedy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

2.  Presentation and management of herpes zoster (shingles) in the geriatric population.

Authors:  Kenneth R Cohen; Rebecca L Salbu; Jerry Frank; Igor Israel
Journal:  P T       Date:  2013-04

3.  Varicella zoster meningoradiculitis in Crohn's disease treated with 6-mercaptopurine.

Authors:  Garret Cullen; Douglas Krakower; Jennifer A Mitty; Adam S Cheifetz
Journal:  Inflamm Bowel Dis       Date:  2011-05-25       Impact factor: 5.325

Review 4.  What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Authors:  Gianluca Andrisani; Alessandro Armuzzi; Manuela Marzo; Carla Felice; Daniela Pugliese; Alfredo Papa; Luisa Guidi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

5.  Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs.

Authors:  F S Hasnie; J Breuer; S Parker; V Wallace; J Blackbeard; I Lever; P R Kinchington; A H Dickenson; T Pheby; A S C Rice
Journal:  Neuroscience       Date:  2006-12-29       Impact factor: 3.590

6.  Characterization of the host immune response in human Ganglia after herpes zoster.

Authors:  Kavitha Gowrishankar; Megan Steain; Anthony L Cunningham; Michael Rodriguez; Peter Blumbergs; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

7.  Productive varicella-zoster virus infection of cultured intact human ganglia.

Authors:  Kavitha Gowrishankar; Barry Slobedman; Anthony L Cunningham; Monica Miranda-Saksena; Ross A Boadle; Allison Abendroth
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

Review 8.  Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia.

Authors:  Pamela S Davies; Bradley S Galer
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  The DNA element controlling expression of the varicella-zoster virus open reading frame 28 and 29 genes consists of two divergent unidirectional promoters which have a common USF site.

Authors:  Min Yang; John Hay; William T Ruyechan
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Varicella-zoster virus IE62 protein utilizes the human mediator complex in promoter activation.

Authors:  Min Yang; John Hay; William T Ruyechan
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.